[ad_1]
According to sources, the Handelsblatt business daily reported Monday that Berlin estimated the vaccine’s effectiveness in people over 65 at just 8 percent.
The tabloid Bild also said that Berlin did not expect that the vaccine, developed by AstraZeneca in collaboration with the University of Oxford and approved by the European Union (EU) this week, would be allowed for use in the elderly, which would be a significant challenge for many. countries vaccination plans.
“Reports that the AstraZeneca and Oxford University vaccine is only 8% effective for adults 65 and older are completely false,” the company said in a statement released Monday night.
“In November, we published data in The Lancet showing that older people had a strong immune response to the vaccine,” the company said.
The European Union issued an outrageous warning to AstraZeneca on Monday about an unexpected delay in delivering millions of doses of vaccines to the unit.
Last Friday, a pharmaceutical giant announced that it would not meet its contractual obligations to deliver the vaccine to the EU due to unexplained disruptions in its supply chain in the EU.
Currently, the EU allows the distribution of two vaccines, one developed by BioNTech and Pfizer and the other by Moderna.
The AstraZeneca vaccine was scheduled to be added to this list this week, as the vaccine had to be ready for immediate distribution.
[ad_2]
